Prize Reinforcement Contingency Management for Cocaine Dependence: a 24-week Randomized Controlled Trial

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Sylvie Petitjean, University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier:
NCT00877435
First received: April 6, 2009
Last updated: May 15, 2013
Last verified: May 2013
  Purpose

The purpose of this study is to determine whether prize reinforcement contingency management combined with cognitive behavioral therapy (CBT) is effective in the treatment of patients with a cocaine dependence compared to CBT alone. Patients are treated over 24 weeks. It is the second trial of this type in Europe.


Condition Intervention
Cocaine-related Disorders
Behavioral: Cognitive behavioral therapy

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: Prize Reinforcement Contingency Management for Cocaine Dependence: a 24-week Randomized Controlled Trial

Further study details as provided by University Hospital, Basel, Switzerland:

Primary Outcome Measures:
  • cocaine abstinence, retention in treatment [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • satisfaction with the therapy [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]

Enrollment: 80
Study Start Date: September 2008
Estimated Study Completion Date: August 2013
Estimated Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Cognitive behavioral therapy (CBT) + Contingency Management (CM)
Behavioral: Cognitive behavioral therapy
Cognitive behavioral therapy and prize reinforced contingency management
Active Comparator: 2
Cognitive behavioral therapy (CBT)
Behavioral: Cognitive behavioral therapy
Cognitive behavioral therapy and prize reinforced contingency management

  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • cocaine dependence, aged 18 or older, other dependences

Exclusion Criteria:

  • severe somatic, brain, or psychiatric disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00877435

Locations
Switzerland
Universitäre Psychiatrischen Kliniken
Basel, Switzerland, 4025
Fondation Phenix
Geneva, Switzerland, 1221
Sponsors and Collaborators
University Hospital, Basel, Switzerland
Investigators
Principal Investigator: Sylvie A Petitjean, Dr. phil. Psychiatric Hospital of the University of Basel
  More Information

Additional Information:
No publications provided

Responsible Party: Sylvie Petitjean, Dr. phil, University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier: NCT00877435     History of Changes
Other Study ID Numbers: SNF-105314-120675
Study First Received: April 6, 2009
Last Updated: May 15, 2013
Health Authority: Switzerland: Ethikkommission
Switzerland: Swissmedic

Additional relevant MeSH terms:
Cocaine-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Substance-Related Disorders

ClinicalTrials.gov processed this record on October 20, 2014